Of clinical interest, we find that TET2 deficiency renders CebpaDM AML sensitive to 5-AZA and that TET2-deficient cells lose their proliferative advantage over TET2-proficient cells following 5-AZA treatment. This evidence concerns the gene TET2 and acute myeloid leukemia.